Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma

Fiedor, Elżbieta; Gregoraszczuk, Ewa Ł.

doi:10.1007/s00280-017-3423-5

Cited by 8 publications

(8 citation statements)

References 43 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis also showed that leptin promotes cell cycle progression, as demonstrated by an increased cell population in both the S and G2/M phases [38]. Other studies confirmed twofold higher leptin receptor gene and protein expression in both epithelial ovarian cancer and cancer granulosa cell lines compared to non-cancer cell lines, which is associated with poor treatment prognosis [39, 40]. In addition leptin has also been shown to stimulate the migration and invasion of ovarian cancer cells, regardless of the degree of leptin receptor expression in the cells [36, 37].…”

Section: The Influence Of Leptin On the Development Of Ovarian Cancermentioning

confidence: 99%

The influence of leptin on the process of carcinogenesis

Modzelewska¹,

Chludzińska²,

Lewko³

et al. 2019

View full text Add to dashboard Cite

Obesity is a new risk factor, to which more and more research is devoted, related to the development of cancer. Many studies of recent years have drawn attention to the role of adipose tissue as an important internal endocrine organ. In the adipose tissue proteins are produced, referred to by the common name as adipokines. In the case of obesity, the neoplasm cells are constantly stimulated by pro-inflammatory cytokines and adipokines, among which leptin dominates. The studies show that leptin can affect the cancer cells through numerous phenomena, e.g. inflammation, cell proliferation, suppression of apoptosis and angiogenesis. In this literature review we examined the role of leptin in the development of the individual cancers: breast cancer, colorectal cancer, prostate cancer, ovarian cancer, endometrial cancer and brain neoplasms: glioma and meningioma. However, leptin has very complicated mechanisms of action which require better understanding in certain types of cancer.

show abstract

Section: The Influence Of Leptin On the Development Of Ovarian Cancermentioning

confidence: 99%

The influence of leptin on the process of carcinogenesis

Modzelewska¹,

Chludzińska²,

Lewko³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Whether leptin might regulate angiogenesis in HCC through these pathways requires further confirmation. Several groups have developed compounds or antibodies targeting leptin/Ob-R signaling that show significant anticancer effects in vitro or in vivo , but have not been applied clinically 64 , 65 .…”

Section: Angiogenic Factorsmentioning

confidence: 99%

Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies

Yao

Kong

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated death worldwide. Angiogenesis, the process of formation of new blood vessels, is required for cancer cells to obtain nutrients and oxygen. HCC is a typical hypervascular solid tumor with an aberrant vascular network and angiogenesis that contribute to its growth, progression, invasion, and metastasis. Current anti-angiogenic therapies target mainly tyrosine kinases, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), and are considered effective strategies for HCC, particularly advanced HCC. However, because the survival benefits conferred by these anti-angiogenic therapies are modest, new anti-angiogenic targets must be identified. Several recent studies have determined the underlying molecular mechanisms, including pro-angiogenic factors secreted by HCC cells, the tumor microenvironment, and cancer stem cells. In this review, we summarize the roles of pro-angiogenic factors; the involvement of endothelial cells, hepatic stellate cells, tumor-associated macrophages, and tumor-associated neutrophils present in the tumor microenvironment; and the regulatory influence of cancer stem cells on angiogenesis in HCC. Furthermore, we discuss some of the clinically approved anti-angiogenic therapies and potential novel therapeutic targets for angiogenesis in HCC. A better understanding of the mechanisms underlying angiogenesis may lead to the development of more optimized anti-angiogenic treatment modalities for HCC.

show abstract

“…In our previously published data, we demonstrated that the negative effect of leptin on the proliferation of several epithelial and folliculoma ovarian cancer cells can be partially or completely reversed by leptin receptor antagonist treatment via interactions with cell cycle protein expression (12,13). A number of leptin receptor antagonists have been synthesised for therapeutic use, with several completing preclinical testing (19) indicating their possible use in anticancer therapy.…”

mentioning

confidence: 98%

“…Obesity is a risk factor for several different types of cancer, significantly promoting cancer incidence, progression, poor prognosis and resistance to anti-cancer therapies. The increased risk of ovarian cancer, both epithelial and folliculoma, are correlated with obesity; elevated leptin secretion and higher leptin receptor expression has been described in ovarian cancer versus non-cancer cells (12,13). Although data pointing to the relationship between HDAC and leptin are scarce, it has been reported that HDAC5 expression is regulated by dietary lipids and leptin and hypothalamic HDAC5 is an important component of leptin signalling (14).…”

mentioning

confidence: 99%

“…The next day, the medium was changed and cells were treated with leptin at a dose of 40 ng/ml alone or with SHLA and leptin. Doses of leptin were chosen based on the literature and our previously published paper (12,13,22). Total RNA isolation and cDNA synthesis was performed using the TaqMan Gene Expression Cell-to-CT Kit (Applied Biosystems, Carlsbad, CA, USA) in accordance with the manufacturer's protocol.…”

mentioning

confidence: 99%

See 1 more Smart Citation